Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CalciMedica, Inc.CALC · Entity 7804 | Director | October 01, 2026 | October 05, 2026 |
| SCHWAB CHARLES CORPSCHW · Entity 1218 | Director | December 13, 2018 | December 15, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CalciMedica, Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.64 · Expires 2036-09-30 | Direct | 20,000 |
Reported balance
After 2026-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 20,000 · Balance 20,000 F1: Beginning August 19, 2026, 1/12th of the shares subject to the option vest in equal monthly installments over a one year period, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: Beginning August 19, 2026, 1/12th of the shares subject to the option vest in equal monthly installments over a one year period, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.
SCHWAB CHARLES CORP
Report date December 13, 2018 · Filed December 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 193,282 |
Ending reported balance
After 2018-12-13 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2018-12-13 · Exercise / conversion · Acquired 16,491 · Balance 183,980 Row 2 · 2018-12-13 · Exercise / conversion · Acquired 14,345 · Balance 198,325 Row 3 · 2018-12-13 · Exercise / conversion · Acquired 11,344 · Balance 209,669 Row 4 · 2018-12-13 · Tax withholding · Disposed 4,787 · Balance 204,882 Row 5 · 2018-12-13 · Tax withholding · Disposed 5,000 · Balance 199,882 Row 6 · 2018-12-13 · Tax withholding · Disposed 6,600 · Balance 193,282 |
| Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.62 · Expires 2021-05-19 | Direct | 0 |
Reported balance
After 2018-12-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-12-13 · Exercise / conversion · Disposed 11,344 · Balance 0 F1: The date first exercisable is 5/19/2012. |
| Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.21 · Expires 2023-05-20 | Direct | 0 |
Reported balance
After 2018-12-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-12-13 · Exercise / conversion · Disposed 14,345 · Balance 0 F2: The date first exercisable is 5/20/2014. |
| Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.66 · Expires 2022-05-21 | Direct | 0 |
Reported balance
After 2018-12-13 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-12-13 · Exercise / conversion · Disposed 16,491 · Balance 0 F3: The date first exercisable is 5/21/2013. |
Filing footnotes · ownership attribution and instrument terms
F1: The date first exercisable is 5/19/2012.
F2: The date first exercisable is 5/20/2014.
F3: The date first exercisable is 5/21/2013.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
JOHNSON & JOHNSON
Report date August 19, 2003 · Filed August 21, 2003
Section 16 reporting ended · disclosed 2003-08-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| CommonSEC Table I · non-derivative | Direct | 889,154 |
Ending reported balance
After 2003-08-19 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2003-08-19 · Exercise / conversion · Acquired 36,000 · Balance 925,154 F1: Adjusted to reflect two-for-one stock splits in 1996 and 2001. Row 2 · 2003-08-19 · Sale · Disposed 36,000 · Balance 889,154 |
| CommonSEC Table I · non-derivative | Indirect401 (k) and ESOP Savings Plans | 2,091 |
Reported balance
After 2003-07-31 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2003-07-31 · Other · Acquired 10 · Balance 2,091 F2: Shares acquired under Johnson & Johnson's 401(k) and ESOP Savings Plans as of Plan's most recent reporting date (7/31/2003). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.07 · Expires 2003-12-02 | Direct | 0 |
Reported balance
After 2003-08-19 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2003-08-19 · Exercise / conversion · Disposed 36,000 · Balance 0 F4: Awarded under Issuer's Stock Option Plan and exercisable in increments of 20% per year starting two years from date of grant. F1: Adjusted to reflect two-for-one stock splits in 1996 and 2001. |
| CommonSEC Table I · non-derivative | IndirectIn Trust for Son | 19,600 |
Reported balance
Holding disclosure · report date 2003-08-19 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 19,600 F3: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
| CommonSEC Table I · non-derivative | IndirectBy Son | 800 |
Reported balance
Holding disclosure · report date 2003-08-19 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 800 F3: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
| CommonSEC Table I · non-derivative | IndirectIn Trust for Daughter | 19,600 |
Reported balance
Holding disclosure · report date 2003-08-19 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 19,600 F3: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
| CommonSEC Table I · non-derivative | IndirectBy Daughter | 800 |
Reported balance
Holding disclosure · report date 2003-08-19 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 800 F3: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
| CommonSEC Table I · non-derivative | IndirectBy Wife | 60,000 |
Reported balance
Holding disclosure · report date 2003-08-19 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 60,000 F3: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
| CommonSEC Table I · non-derivative | IndirectBy GRAT | 110,232 |
Reported balance
Holding disclosure · report date 2003-08-19 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 110,232 |
Filing footnotes · ownership attribution and instrument terms
F1: Adjusted to reflect two-for-one stock splits in 1996 and 2001.
F2: Shares acquired under Johnson & Johnson's 401(k) and ESOP Savings Plans as of Plan's most recent reporting date (7/31/2003).
F3: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F4: Awarded under Issuer's Stock Option Plan and exercisable in increments of 20% per year starting two years from date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 21:21 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantDirector Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001189022-26-000005 · form4-10052026_091035.xml · derivative · entry 1 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-09-30 F1 · derivative.exercise_date: Beginning August 19, 2026, 1/12th of the shares subject to the option vest in equal monthly installments over a one year period, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 22:42 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001189022-26-000004 · form4-08212026_100838.xml · derivative · entry 3 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-08-18 F4 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 22:42 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 1,182,621 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001189022-26-000004 · form4-08212026_100838.xml · derivative · entry 2 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,182,621 Underlying: Common Stock · 1,182,621 shares Expires 2031-06-25 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F3 · derivative.exercise_date: The warrant may be exercised on or after August 19, 2026, and on or prior to June 25, 2031; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%. F3 · derivative.expiration_date: The warrant may be exercised on or after August 19, 2026, and on or prior to June 25, 2031; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 22:42 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 1,182,621 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001189022-26-000004 · form4-08212026_100838.xml · derivative · entry 1 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,182,621 Underlying: Common Stock · 1,182,621 shares Expires 2027-12-25 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F2 · derivative.exercise_date: The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%. F2 · derivative.expiration_date: The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 12:45 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantCommon Stock | 1,182,621 | $0.80 | $949,999.45 |
DisclosureSEC source: 0001189022-26-000002 · form4-06292026_080605.xml · nonDerivative · entry 1 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,604,650 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. Read SEC document |
| July 18, 2025 Filed Jul 18, 2025 18:42 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 4,500 | $2.87 | $12,915.00 |
DisclosureSEC source: 0001415889-25-019998 · form4-07182025_060737.xml · nonDerivative · entry 1 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 422,029 Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 22:20 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001415889-25-018298 · form4-06262025_100600.xml · derivative · entry 4 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-06-23 F5 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following June 24, 2025, provided that the shares will in any case be fully vested on the date of Company's 2026 annual meeting of stockholders. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 22:20 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantDirector Stock Option (Right to Buy) · Derivative | 36,562 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001415889-25-018298 · form4-06262025_100600.xml · derivative · entry 3 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,562 Underlying: Common Stock · 36,562 shares Expires 2035-04-22 F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025. F4 · derivative.exercise_date: 1/9th of the shares subject to the option vest in equal monthly installments over a one year period following April 1, 2025. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 22:20 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantDirector Stock Option (Right to Buy) · Derivative | 12,031 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001415889-25-018298 · form4-06262025_100600.xml · derivative · entry 2 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,031 Underlying: Common Stock · 12,031 shares Expires 2035-04-22 F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 22:20 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001415889-25-018298 · form4-06262025_100600.xml · derivative · entry 1 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-04-22 F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025. F2 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 26, 2025. Read SEC document |
| November 01, 2024 Filed Nov 1, 2024 17:22 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 53,333 | $3.75 | $199,998.75 |
DisclosureSEC source: 0001415889-24-025876 · form4-11012024_051102.xml · nonDerivative · entry 1 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 417,529 Read SEC document |
| August 27, 2024 Filed Aug 28, 2024 23:12 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-022505 · form4-08282024_110857.xml · derivative · entry 1 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-08-26 F1 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 28, 2024. Read SEC document |
| August 23, 2024 Filed Aug 26, 2024 21:57 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 54,000 | $3.72 | $200,826.00 |
DisclosureSEC source: 0001415889-24-022242 · form4-08262024_090826.xml · nonDerivative · entry 1 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364,196 F1 · price: The weighted average purchase price for the transaction reported was $3.719, and the range of prices were between $3.50 and $3.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 20:50 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 51,278 | $3.52 | $180,498.56 |
DisclosureSEC source: 0001415889-24-018934 · form4-07022024_080711.xml · nonDerivative · entry 1 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 310,196 F1 · price: The weighted average purchase price for the transaction reported was $3.52, and the range of prices were between $3.2997 and $3.7935. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 19:12 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 8,443 | $3.23 | $27,304.66 |
DisclosureSEC source: 0001415889-24-018567 · form4-07012024_070708.xml · nonDerivative · entry 1 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 258,918 F1 · price: The weighted average purchase price for the transaction reported was $3.234, and the range of prices were between $3.17 and $3.24. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| March 28, 2024 Filed Apr 23, 2024 01:43 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-011350 · form4-04232024_010454.xml · derivative · entry 1 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-03-27 F1 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 01:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 34,157 | $0.13 Strike: $7.15 | $4,269.63 |
DisclosureSEC source: 0001415889-24-001829 · form4-01252024_080102.xml · derivative · entry 3 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,157 Underlying: Common Stock · 34,157 shares Expires 2026-12-31 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F3 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. F3 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 01:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 34,157 | $0.13 Strike: $5.36 | $4,269.63 |
DisclosureSEC source: 0001415889-24-001829 · form4-01252024_080102.xml · derivative · entry 2 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,157 Underlying: Common Stock · 34,157 shares Expires 2024-12-31 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F2 · derivative.exercise_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. F2 · derivative.expiration_date: The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 01:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantCommon Stock | 68,314 | $4.27 | $291,461.68 |
DisclosureSEC source: 0001415889-24-001829 · form4-01252024_080102.xml · nonDerivative · entry 1 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,475 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. Read SEC document |
| December 11, 2023 Filed Dec 14, 2023 01:45 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 506 | $3.30 | $1,669.80 |
DisclosureSEC source: 0001209191-23-058568 · doc4.xml · nonDerivative · entry 1 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,161 Read SEC document |
| May 08, 2023 Filed Jun 28, 2023 23:52 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantDirector Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001209191-23-040098 · doc4.xml · derivative · entry 1 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-05-07 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest in equal monthly installments over a three year period following the date of grant. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:52 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 8,592 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-020682 · doc4.xml · derivative · entry 8 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,592 Underlying: Common Stock · 8,592 shares Expires 2026-06-25 F11 · price: Received in exchange for a warrant to purchase 298,321 shares of common stock of CalciMedica pursuant to the Merger Agreement. F10 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:52 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 8,592 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-020682 · doc4.xml · derivative · entry 7 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,592 Underlying: Common Stock · 8,592 shares Expires 2026-02-22 F11 · price: Received in exchange for a warrant to purchase 298,321 shares of common stock of CalciMedica pursuant to the Merger Agreement. F10 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:52 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantDirector Stock Option (right to buy) · Derivative | 1,488 | Not disclosed Strike: $17.34 | Not disclosed |
DisclosureSEC source: 0001209191-23-020682 · doc4.xml · derivative · entry 6 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,488 Underlying: Common Stock · 1,488 shares Expires 2033-03-19 F3 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F9 · price: Received in exchange for a stock option to acquire 51,692 shares of common stock of CalciMedica pursuant to the Merger Agreement. F5 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of twelve (12) successive equal monthly installments. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:52 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantDirector Stock Option (right to buy) · Derivative | 7,577 | Not disclosed Strike: $17.34 | Not disclosed |
DisclosureSEC source: 0001209191-23-020682 · doc4.xml · derivative · entry 5 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,577 Underlying: Common Stock · 7,577 shares Expires 2033-03-19 F3 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F8 · price: Received in exchange for a stock option to acquire 263,107 shares of common stock of CalciMedica pursuant to the Merger Agreement. F5 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of twelve (12) successive equal monthly installments. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:52 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantDirector Stock Option (right to buy) · Derivative | 5,760 | Not disclosed Strike: $7.99 | Not disclosed |
DisclosureSEC source: 0001209191-23-020682 · doc4.xml · derivative · entry 4 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,760 Underlying: Common Stock · 5,760 shares Expires 2031-06-30 F3 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F7 · price: Received in exchange for a stock option to acquire 200,000 shares of common stock of CalciMedica pursuant to the Merger Agreement. F6 · derivative.exercise_date: Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:52 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantDirector Stock Option (right to buy) · Derivative | 5,760 | Not disclosed Strike: $7.99 | Not disclosed |
DisclosureSEC source: 0001209191-23-020682 · doc4.xml · derivative · entry 3 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,760 Underlying: Common Stock · 5,760 shares Expires 2031-04-27 F3 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F7 · price: Received in exchange for a stock option to acquire 200,000 shares of common stock of CalciMedica pursuant to the Merger Agreement. F5 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of twelve (12) successive equal monthly installments. F6 · derivative.exercise_date: Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:52 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantDirector Stock Option (right to buy) · Derivative | 23,557 | Not disclosed Strike: $6.60 | Not disclosed |
DisclosureSEC source: 0001209191-23-020682 · doc4.xml · derivative · entry 2 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,557 Underlying: Common Stock · 23,557 shares Expires 2030-06-29 F3 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F4 · price: Received in exchange for a stock option to acquire 817,964 shares of common stock of CalciMedica pursuant to the Merger Agreement. F2 · derivative.exercise_date: Beginning on June 15, 2020, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:52 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantCommon Stock | 181,655 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-020682 · doc4.xml · nonDerivative · entry 1 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,655 F1 · price: Received in exchange for 6,307,451 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. Read SEC document |
| December 13, 2018 Filed Dec 15, 2018 00:13 UTC | SCHWAB CHARLES CORP SCHW · Entity 1218 | Exercise / conversionNonqualified Stock Option (right to buy) · Derivative | 16,491 | $0.00 Strike: $12.66 | $0.00 |
DisclosureSEC source: 0001225208-18-016661 · doc4.xml · derivative · entry 9 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,491 shares Expires 2022-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The date first exercisable is 5/21/2013. Read SEC document |
| December 13, 2018 Filed Dec 15, 2018 00:13 UTC | SCHWAB CHARLES CORP SCHW · Entity 1218 | Exercise / conversionNonqualified Stock Option (right to buy) · Derivative | 14,345 | $0.00 Strike: $19.21 | $0.00 |
DisclosureSEC source: 0001225208-18-016661 · doc4.xml · derivative · entry 8 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,345 shares Expires 2023-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The date first exercisable is 5/20/2014. Read SEC document |
| December 13, 2018 Filed Dec 15, 2018 00:13 UTC | SCHWAB CHARLES CORP SCHW · Entity 1218 | Exercise / conversionNonqualified Stock Option (right to buy) · Derivative | 11,344 | $0.00 Strike: $17.62 | $0.00 |
DisclosureSEC source: 0001225208-18-016661 · doc4.xml · derivative · entry 7 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,344 shares Expires 2021-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The date first exercisable is 5/19/2012. Read SEC document |
| December 13, 2018 Filed Dec 15, 2018 00:13 UTC | SCHWAB CHARLES CORP SCHW · Entity 1218 | Tax withholdingCommon Stock | 6,600 | $41.75 | $275,533.50 |
DisclosureSEC source: 0001225208-18-016661 · doc4.xml · nonDerivative · entry 6 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,282 Read SEC document |
| December 13, 2018 Filed Dec 15, 2018 00:13 UTC | SCHWAB CHARLES CORP SCHW · Entity 1218 | Tax withholdingCommon Stock | 5,000 | $41.75 | $208,737.50 |
DisclosureSEC source: 0001225208-18-016661 · doc4.xml · nonDerivative · entry 5 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,882 Read SEC document |
| December 13, 2018 Filed Dec 15, 2018 00:13 UTC | SCHWAB CHARLES CORP SCHW · Entity 1218 | Tax withholdingCommon Stock | 4,787 | $41.75 | $199,845.28 |
DisclosureSEC source: 0001225208-18-016661 · doc4.xml · nonDerivative · entry 4 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,882 Read SEC document |
| December 13, 2018 Filed Dec 15, 2018 00:13 UTC | SCHWAB CHARLES CORP SCHW · Entity 1218 | Exercise / conversionCommon Stock | 11,344 | $17.62 | $199,881.28 |
DisclosureSEC source: 0001225208-18-016661 · doc4.xml · nonDerivative · entry 3 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2018 Filed Dec 15, 2018 00:13 UTC | SCHWAB CHARLES CORP SCHW · Entity 1218 | Exercise / conversionCommon Stock | 14,345 | $19.21 | $275,567.45 |
DisclosureSEC source: 0001225208-18-016661 · doc4.xml · nonDerivative · entry 2 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2018 Filed Dec 15, 2018 00:13 UTC | SCHWAB CHARLES CORP SCHW · Entity 1218 | Exercise / conversionCommon Stock | 16,491 | $12.66 | $208,776.06 |
DisclosureSEC source: 0001225208-18-016661 · doc4.xml · nonDerivative · entry 1 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,980 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2018 Filed May 21, 2018 20:22 UTC | SCHWAB CHARLES CORP SCHW · Entity 1218 | GrantNonqualified Stock Option (right to buy) · Derivative | 5,139 | $0.00 Strike: $59.32 | $0.00 |
DisclosureSEC source: 0001225208-18-009626 · doc4.xml · derivative · entry 2 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,139 Underlying: Common Stock · 5,139 shares Expires 2018-05-17 F2 · derivative.exercise_date: The option was granted under the company's 2013 Stock Incentive Plan and vests 25% on the first and second anniversary of the grant date and 50% on the third anniversary of the grant date. Read SEC document |
| May 17, 2018 Filed May 21, 2018 20:22 UTC | SCHWAB CHARLES CORP SCHW · Entity 1218 | GrantCommon Stock | 1,351 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009626 · doc4.xml · nonDerivative · entry 1 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,489 F1 · shares: The reported transaction constitutes a grant of restricted stock units, which were granted under the company's 2013 Stock Incentive Plan and vest 25% on the first and second anniversary of the grant date and 50% on the third anniversary of the grant date. Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 22:27 UTC | SCHWAB CHARLES CORP SCHW · Entity 1218 | Exercise / conversionNonqualified Stock Option (right to buy) · Derivative | 7,486 | $0.00 Strike: $22.39 | $0.00 |
DisclosureSEC source: 0001225208-17-016439 · doc4.xml · derivative · entry 9 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,486 shares Expires 2018-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 22:27 UTC | SCHWAB CHARLES CORP SCHW · Entity 1218 | Exercise / conversionNonqualified Stock Option (right to buy) · Derivative | 8,356 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001225208-17-016439 · doc4.xml · derivative · entry 8 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,356 shares Expires 2019-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 22:27 UTC | SCHWAB CHARLES CORP SCHW · Entity 1218 | Exercise / conversionNonqualified Stock Option (right to buy) · Derivative | 11,082 | $0.00 Strike: $17.38 | $0.00 |
DisclosureSEC source: 0001225208-17-016439 · doc4.xml · derivative · entry 7 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,082 shares Expires 2020-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option was first exercisable on May 17, 2011. Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 22:27 UTC | SCHWAB CHARLES CORP SCHW · Entity 1218 | Tax withholdingCommon Stock | 4,427 | $43.50 | $192,568.30 |
DisclosureSEC source: 0001225208-17-016439 · doc4.xml · nonDerivative · entry 6 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,138 Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 22:27 UTC | SCHWAB CHARLES CORP SCHW · Entity 1218 | Tax withholdingCommon Stock | 3,853 | $43.50 | $167,600.11 |
DisclosureSEC source: 0001225208-17-016439 · doc4.xml · nonDerivative · entry 5 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,565 Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 22:27 UTC | SCHWAB CHARLES CORP SCHW · Entity 1218 | Tax withholdingCommon Stock | 3,457 | $43.50 | $150,374.66 |
DisclosureSEC source: 0001225208-17-016439 · doc4.xml · nonDerivative · entry 4 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,418 Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 22:27 UTC | SCHWAB CHARLES CORP SCHW · Entity 1218 | Exercise / conversionCommon Stock | 7,486 | $22.39 | $167,611.54 |
DisclosureSEC source: 0001225208-17-016439 · doc4.xml · nonDerivative · entry 3 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 22:27 UTC | SCHWAB CHARLES CORP SCHW · Entity 1218 | Exercise / conversionCommon Stock | 8,356 | $18.00 | $150,408.00 |
DisclosureSEC source: 0001225208-17-016439 · doc4.xml · nonDerivative · entry 2 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 22:27 UTC | SCHWAB CHARLES CORP SCHW · Entity 1218 | Exercise / conversionCommon Stock | 11,082 | $17.38 | $192,605.16 |
DisclosureSEC source: 0001225208-17-016439 · doc4.xml · nonDerivative · entry 1 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2017 Filed May 22, 2017 18:14 UTC | SCHWAB CHARLES CORP SCHW · Entity 1218 | GrantNonqualified Stock Option (right to buy) · Derivative | 7,165 | $0.00 Strike: $38.33 | $0.00 |
DisclosureSEC source: 0001225208-17-010172 · doc4.xml · derivative · entry 2 WILSON ROBERT N · CIK 0001189022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,165 Underlying: Common Stock · 7,165 shares Expires 2027-05-18 F2 · derivative.exercise_date: The option was granted under the company's 2013 Stock Incentive Plan and vests 25% on the first and second anniversary of the grant date and 50% on the third anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.